R&D channel feed – Endpoints News

R&D channel feed

Wave Life Sciences touts Huntington's disease win in Phase 1b/2a trial

10 months ago

J&J's Tremfya fails giant cell arteritis study, where Roche and AbbVie have succeeded

10 months ago

AstraZeneca’s Imfinzi aces Phase 3 test in bladder cancer, fails another in lung cancer

10 months ago

Ex-Meta scientists launch EvolutionaryScale with $142M seed round, unveiling next-gen AI model for protein design

10 months ago

Merck KGaA's bet on head and neck cancer drug from Debiopharm ends in Phase 3 failure

10 months ago

Phase 3 breast cancer failure leads to staff cuts, stock drop at G1 Therapeutics

10 months ago

Novo reveals more hemophilia A data showing superiority in annualized bleeding rates

10 months ago

Gilead, Viking and Biohaven detail promising preclinical research in obesity and NASH

10 months ago

Lykos’ pain is others’ gain as psychedelic biotechs take notes from adcomm vote

10 months ago

Amylyx, searching for post-ALS future, licenses a GLP-1 drug

10 months ago

Altimmune says ‘double G’ drug has even better lean mass preservation data in obesity trial update

10 months ago

Alnylam’s RNAi therapy succeeds in closely-watched Phase 3 heart trial

10 months ago

Fractyl pitches potential of GLP-1 gene therapy, but pushes clinical trials back to 2025

10 months ago

Three of Vertex’s islet cell therapy patients go insulin-independent

10 months ago

Lilly’s Zepbound resolves sleep apnea in obese patients, furthering case for label expansion

10 months ago

Gilead's twice-a-year injection fully prevented HIV in Phase 3 study with cisgender women

10 months ago

Scientists just discovered a new genetic clue for delaying Alzheimer’s disease. It’s already inspiring drug discovery

10 months ago

Zealand Pharma hits early efficacy goal for amylin weight loss candidate

10 months ago

Jazz's stock dips after mid-stage fail in essential tremor

10 months ago

PTC touts Phase 2 biomarker data for Huntington’s drug, showing dose-dependent effect at one year

10 months ago

Silence’s siRNA candidate for cardiovascular disease continues to deliver in Phase 2 trial

10 months ago

Aphaia hits primary endpoint with oral glucose drug in mid-stage prediabetes trial

10 months ago

iOnctura raises €80M to advance early-stage rare eye cancer treatment

10 months ago

Intra-Cellular reports a depression win, setting up future competition with AbbVie's Vraylar

11 months ago

First page Previous page 36 37 383940 41 42 Next page Last page